Rafael J ARGUELLO

About

ARGÜELLO, Rafael José. (24/12/1982)

CRCN (2018), CNRS, France (Tenured)

Marseille-Luminy Immunology Center (CIML), Marseille.

ORCID: https://orcid.org/0000-0001-9785-3883

Emerging leadership scholar, International Society for the Advancement of Cytometry (ISAC)

Co-founder of the European ImmunoMetabolism Network – Communications workgroup leader

Co-founder of GammaOmics – (Scientific advisor)

Molecular Immunologist & Innovator. I am a molecular immunologist and Research Scientist (CRCN) at CNRS in Marseille, leading the Metabolic Regulation of Immunity team, (hosted by PPlab, CIML). My scientific path began with a PhD in Human Immunology from the University of Buenos Aires, where limited resources fostered a commitment to innovation. I continued with postdoctoral training at CIML (PP-lab) and the University of California, San Francisco (UCSF), focusing on translation control, epi-transcriptomics, and human cancer immunometabolism.

My research seeks to understand how metabolic changes regulate long-term immune programming through epigenetic mechanisms. To achieve this, I develop and apply innovative single-cell and spatial methods. I am the inventory of SCENITH™, a patented and widely adopted assay for functional metabolic profiling, and I have expanded this approach into derivatives such as Epic-SCENITH and Spatial-SCENITH. These tools are now used to dissect therapy resistance in leukemia, tumor–immune interactions in glioblastoma, and long-term immune dysfunction after sepsis. I have organized multiple educational workshops and trained students at all levels.

Alongside academic work, I co-founded GammaOmics, a biotechnology start-up that holds the exclusive license for SCENITH™, extending CNRS innovation into the field of personalized medicine. I am part of the steering committee and also serve as communications lead of the European ImmunoMetabolism Network, where I help to coordinate training, collaborations, and dissemination across more than 400 researchers in Europe.

My goal is to continue bridging fundamental immunology with translational applications, advancing both mechanistic knowledge and the development of biomarkers and therapeutic strategies. By combining methodological innovation, clinical collaborations, and international leadership, I aim to strengthen the visibility and impact of CNRS in the emerging field of human immunometabolism.